Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Prestige OTCs up, personal care down: The drug and personal care product marketer and distributor reports a 5.6 percent increase to $47.6 million in net revenues for its OTC segment during its fiscal 2008 third quarter, although total company net revenues were flat and total net income dropped 4.8 percent to $8 million. Diluted earnings per share for the October-December period fell from 17 cents to 16 cents. A busy cold and flu season drove Prestige Brands' OTC growth with its Chloraseptic and Little Remedies brands, as well as the Allergen Block line of preventive drug-free gels launched in 2008 (1"The Tan Sheet" Nov. 10, 2008, p. 15). Declines in Murine and Clear Eyes eye care brands partially offset other OTC gains, but Chairman and CEO Mark Pettie says a new "eight hours of soothing relief" claim for Clear Eyes will help drive growth. Total revenues for the Irvington, N.Y.-based firm's personal care business fell 10.2 percent from the year-ago period, because of what Pettie called "anticipated declines" in sales of Denorex dandruff shampoo. Sales of wart removers Compound W and Wartner also fell, Prestige reports. Pettie calls Prestige's free cash flow a "bright spot," but says the firm is unlikely to meet its 2 percent to 4 percent anticipated long-term growth rate in 2009

You may also be interested in...



Drugstore.com builds on supplement, skin care sales

A 22 percent increase in vitamin and supplement revenue helped the e-retailer increase its first quarter net sales 6.2 percent to $98.3 million - a quarterly record. In an April 29 earnings call, drugstore.com also touted its growing skin care business, up 26 percent, and the 13 percent growth of its vision segment for the three months ending March 29. Overall OTC revenue rose 11 percent, "well ahead of recent e-commerce industry trends," Chairman and CEO Dawn Lepore said. OTC order growth jumped 14 percent in the first quarter, but average basket size contracted, reflecting the economic environment. The Bellevue, Wash.-based firm eked out a profit of $1.3 million for the quarter, due largely to a $1.2 million one-time benefit from the resolution of a sales tax disagreement with New Jersey (1"The Tan Sheet" Feb. 9, 2009, p. 15)

Drugstore.com builds on supplement, skin care sales

A 22 percent increase in vitamin and supplement revenue helped the e-retailer increase its first quarter net sales 6.2 percent to $98.3 million - a quarterly record. In an April 29 earnings call, drugstore.com also touted its growing skin care business, up 26 percent, and the 13 percent growth of its vision segment for the three months ending March 29. Overall OTC revenue rose 11 percent, "well ahead of recent e-commerce industry trends," Chairman and CEO Dawn Lepore said. OTC order growth jumped 14 percent in the first quarter, but average basket size contracted, reflecting the economic environment. The Bellevue, Wash.-based firm eked out a profit of $1.3 million for the quarter, due largely to a $1.2 million one-time benefit from the resolution of a sales tax disagreement with New Jersey (1"The Tan Sheet" Feb. 9, 2009, p. 15)

Drugstore.com builds on supplement, skin care sales

A 22 percent increase in vitamin and supplement revenue helped the e-retailer increase its first quarter net sales 6.2 percent to $98.3 million - a quarterly record. In an April 29 earnings call, drugstore.com also touted its growing skin care business, up 26 percent, and the 13 percent growth of its vision segment for the three months ending March 29. Overall OTC revenue rose 11 percent, "well ahead of recent e-commerce industry trends," Chairman and CEO Dawn Lepore said. OTC order growth jumped 14 percent in the first quarter, but average basket size contracted, reflecting the economic environment. The Bellevue, Wash.-based firm eked out a profit of $1.3 million for the quarter, due largely to a $1.2 million one-time benefit from the resolution of a sales tax disagreement with New Jersey (1"The Tan Sheet" Feb. 9, 2009, p. 15)

Related Content

Topics

UsernamePublicRestriction

Register

PS102594

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel